Adjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes
|
|
- Edward Gilbert
- 6 years ago
- Views:
Transcription
1 Adjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes Brian Hardy, PharmD, FCSHP, FCCP Coordinator Education and Clinical Programs Department of Pharmacy Sunnybrook Health Sciences Centre November 18 th,
2 Presenter Disclosure : Brian Hardy I have no current relationships with commercial entities I have received no speaker s fee for this learning activity 2
3 Commercial Support Disclosure This learning activity has received no financial or in-kind support from any commercial or other organization 3
4 Learning Objectives On completion of the workshop participants should be able to: Understand the pharmacokinetic characteristics of phenytoin, and why we monitor serum phenytoin concentrations. Adjust the observed total serum phenytoin concentration in complex patients with low albumin and/or renal dysfunction Design a dosing schedule for a patient receiving phenytoin based on one steady-state serum level using a population-based estimation technique (i.e. Bayesian nomogram). Demonstrate the ability to individualize phenytoin dosage for a specific patient based on two steady-state serum concentrations. 4
5 Why Monitor Serum Phenytoin Concentrations? Good correlation between the degree of seizure control and serum drug levels Relationship between the type & severity of phenytoin CNS toxicity and serum drug levels Poor correlation between daily dose and achievable steady-state serum drug concentrations Narrow therapeutic index Nonlinear (dose-dependent) kinetics Large inter-subject variability in metabolism Numerous drug-drug interactions 5
6 Relationship between seizure control and phenytoin serum concentrations Eur Neurol 1979,18: Therapeutic Range: mg/l 6
7 Why Monitor Serum Phenytoin Concentrations? Good correlation between the degree of seizure control and serum drug levels Strong relationship between the type & severity of phenytoin CNS toxicity and serum drug levels Poor correlation between daily dose and achievable steady-state serum drug concentrations Narrow therapeutic index Nonlinear (dose-dependent) kinetics Large inter-subject variability in metabolism Numerous drug-drug interactions 7
8 What is the Clinical Presentation of Phenytoin Toxicity? 1. Mild Toxicity ( µmol/l) Far lateral nystagmus 2. Moderate Toxicity ( µmol/l) Ataxia Nystagmus at a 45-degree lateral gaze 3. Severe Toxicity (> 160 µmol/l) Diminished mental capacity Nystagmus, ataxia, involuntary muscular movements, seizures 8
9 Why Monitor Serum Phenytoin Concentrations? Good correlation between the degree of seizure control and serum drug levels Relationship between the type & severity of phenytoin CNS toxicity and serum drug levels Poor correlation between daily dose and achievable steady-state serum drug concentrations Narrow therapeutic index Nonlinear (dose-dependent) kinetics Large inter-subject variability in metabolism Numerous drug-drug interactions 9
10 Variation in the percent of patients achieving therapeutic phenytoin concentrations with increasing weight-adjusted dose Baltimore University Park Press: 1972;
11 Why Monitor Serum Phenytoin Concentrations? Good correlation between the degree of seizure control and serum drug levels Relationship between the type & severity of phenytoin CNS toxicity and serum drug levels Poor correlation between daily dose and achievable steady-state serum drug concentrations Narrow therapeutic index (40 80 µmol/l) Nonlinear (dose-dependent) kinetics Large inter-subject variability in metabolism Numerous drug-drug interactions 11
12 Pharmacokinetic Drug Interactions: Drug Effects on Phenytoin Decreased Phenytoin Absorption Increased Phenytoin Metabolism Decreased Phenytoin Metabolism Enteral Feeds Charcoal Antacids Folic Acid Alcohol Dexamethasone Low Dose Phenobarbital Topiramate Azoles Oxcarbazepine Chloramphenicol Disulfiram Isoniazid Sucralfate Theophylline Antineoplastics Diazepam Rifampin Nitrofurantoin Carbamazepine Cimetidine Amiodarone Allopurinol Omeprazole Sulfonamides High dose Barbiturates (Clin Pharmacokinet 1990;18:37-60) 12
13 Pharmacokinetic Drug Interactions: Effects of Phenytoin on Other Drugs Phenytoin is an enzyme inducer and decreases the serum concentrations of: Rivaroxaban Apixaban Ticagrelor Many HIV anti-retroviral drug Oral contraceptives Vitamin D 13
14 Pharmacokinetic Characteristics of Phenytoin (ADME) 14
15 Absorption Oral Absorption Bioavailability (85-95%) Parenteral Absorption Intravenous route (40% propylene glycol and 10% alcohol diluent adjusted to a ph of 12 with NaOH, maximum infusion rate of 50 mg/min; not greater than 25 mg/min in the elderly or patients with CVD, limited by compatible iv solutions, use an inline filter) Intramuscular route (erratic absorption) 15
16 Distribution and Protein Binding Apparent volume of distribution ( L/kg) (we will use 1.0) Plasma protein binding (88-92%) (we will use 90%) Factors altering protein binding Decreased serum albumin concentration Burns Cirrhosis Nephrotic syndrome Pregnancy Cystic fibrosis Apparent decrease in affinity for serum albumin Renal failure Jaundice (severe) Other highly protein-bound drugs (displacers) 16
17 Metabolism Biotransformation to inactive metabolites by CYP2C9 and CYP2C19 Saturable hepatic enzymes within the therapeutic range (capacity-limited metabolism) Non-linear pharmacokinetics (Michaelis-Menten kinetics) Less than 5% is excreted unchanged renally Large intra-subject variability in metabolism 17
18 Phenytoin Non-Linear Kinetics Brian: Insert Diagram here 18
19 Michaelis-Menten Kinetics R = Vmax x Css Km + Css R = Vmax Km x (R/Css) Where: R (mg/day), Vmax (mg/day), Km (mg/l), Css (mg/l) 19
20 Concepts of Clearance and Half-Life CL = Vmax / (Km + C(t)) = R / Css T ½ = x (Vd/CL) = x Vd (Km + C (t)) Vmax 20
21 Brian: Insert Diagram here 21
22 Select Conditions Affecting the Metabolism of Phenytoin Condition or Disease Example Vmax increased Enzyme induction Concurrent administration of phenobarbital or carbamazepine Vmax decreased Hepatic cirrhosis Decreased enzyme activity is assumed to be the major effect Km increased Km decreased Competitive inhibition Decreased plasma protein binding Concurrent administration of cimetidine or chloramphenicol Decreased serum albumin or presence of displacers such as valproic acid or salicylate 22
23 Time to a Steady-State Plateau t 90% = Km x Vd ((2.303 x Vmax) (0.9 x R)) (Vmax R) 2 Where: R (mg/day), Vmax (mg/day), Km (mg/l), Vd (L), t 90% (days) 23
24 Time to Plateau Brian: Insert Diagram here 24
25 Adjustment of a Observed Total Phenytoin Concentration for Decreased Albumin and/or Renal Function Hypoalbuminemia: Cadjusted = Cobserved (What is Cadjusted?) 0.9 * (albumin/4.4) Severe Renal Disease: Reduce target concentration by one-half See equivalent target concentration ranges - Figure (next slide) Renal Disease and Hypoalbuminemia: Cadjusted = Cobserved 0.1 * (albumin) (or Liponi Method) Where albumin is in g/dls; g/l (SI Units) / 10 = g/dl 25
26 Phenytoin Concentrations that are Equivalent to µg/ml for Patients with Diminished Renal Function The values reflect average binding data: No correction is made for serum albumin. Brian: Insert Diagram here Liponi DF, Winter ME, Tozer TN. Renal function and therapeutic concentrations of phenytoin. Neurology 1984; 34:
27 Estimation of free fraction (f) in Patients with Combined Renal Dysfunction and/or Low Albumin f = nka (P) Cadjusted = Cobserved x (f / 0.1) Where f = free fraction P = Protein = albumin (g/dl); g/l (SI units)/10 = g/dl n = # of binding sites and Ka = the binding affinity constant nka = product of the binding parameters (dl/g) 27
28 Estimation of free fraction (f) in Patients with Combined Renal Dysfunction and/or Low Albumin Brian: Insert Diagram here 28
29 Exercise #1 Adjustment of the observed total serum phenytoin concentration based on decreased albumin levels and/or renal dysfunction A 66 year old male (weight 76 kg) with an observed total serum phenytoin level of 80 µmol/l, albumin of 36 mg/l and serum creatinine of 120 µmol/l is exhibiting signs of CNS toxicity. 1. Estimate the free fraction (f) of phenytoin in this patient. 2. What is the adjusted total serum phenytoin concentration (Cadjusted) in this patient? 29
30 Exercise #1 Adjustment of the observed total serum phenytoin concentration based on decreased albumin levels and/or renal dysfunction Estimate the free fraction (f) of phenytoin in this patient 1. Creatinine Clearance (CrCL) estimate: CrCl (ml/min)(male) = (140-age) (TBW (kg) x 60) 50 x SCr (µmol/l) = (140 66) (76 x 60) 50 x 120 = 56 ml/min 2. Estimate the nka (binding affinity) parameter (see Table) 30
31 Exercise #1 Adjustment of the observed total serum phenytoin concentration based on decreased albumin levels and/or renal dysfunction 31
32 Exercise #1 Adjustment of the observed total serum phenytoin concentration based on decreased albumin levels and/or renal dysfunction 2. Estimate the nka (binding affinity) parameter: For Group II (CrCl ml/min) the nka estimate = 1.6 dl/g 3. Conversion of Albumin concentration: Protein = Albumin = 36mg/L (SI units) = 3.6 mg/dl = P 4. Free fraction estimation: f = 1 = 1 = nka (P) 1 + (1.6 x 3.6) 5. Cadjusted = Cobserved x (f / 0.1) = 80 µmol/l x (0.148/0.1) = 118 µmol/l 32
33 Methods of Dosage Adjustment Based on Css Levels 1. Adjustment based on a population estimate of Km and one Css level (equation) 2. Adjustment based on probable values of Vmax and Km and one Css level (Bayesian prediction) 3. Adjustment based on two Css levels at different daily doses (equation) 33
34 Adjustment based on a population estimate of Km and one Css phenytoin level Equation: Vmax = R + Km x (R/Css) Given: Km = 4 mg/l R = 300 mg/day Css = 8 mg/l (32 µmol/l) Solve for Vmax = R + Km x (R/Css) = x (300/8) = 450 mg/day Then: R = Vmax x Css = 450 x 15 = 355 mg/day Km + Css Where: Css (desired) = 15 mg/l (60 µmol/l) Dose rounded to 360 mg (3 x 100mg & 2 x 30 mg) 34
35 Adjustment based on probable values of Vm and Km and one Css level - Bayesian Nomogram Brian: Insert Diagram here Observed total phenytoin steady-state level on 300mg/day (300mg/70kg = 4.29 mg/kg/day) was 8 mg/l Estimated dose required for target level of 15mg/L is 5.2 mg/kg/day (~ 360 mg/day) 35
36 Adjustment based on two Css levels at different doses Equation: R = Vmax - Km * (R/Css) Given: R (mg/day) Css (mg/l) R/Css (L) Find: R (mg/day) producing a desired Css = 15 mg/l (60 µmol/l) 36
37 Adjustment based on two Css levels at different doses Solution: Km = -slope = - Y2 Y1 = = 11.4 mg/l X2 X Vmax = R + Km (R/Css) = (300/8) = mg/day For Css (desired) = 15 mg/l (60 µmol/l) R = Vmax x Css = x 15 = mg Km + Css Round dose to commercially available dosage: 400mg (4 x 100 mg) 37
38 Exercise #2 Adjustment based on probable values of Vmax and Km and one Css level - Bayesian Nomogram A 23 year old man (75 kg) presented to the ER on 0600h with severe head trauma following a MVA. The patient has no significant past medical history, serum creatinine 85 µmol/l, albumin 35 g/l, normal LFTs. An oral maintenance dose of 300 mg phenytoin sodium was started 11 weeks ago and a steady-state serum phenytoin trough level (@ 0800h on ) was 22 µmol/l (therapeutic range µmol/l). 1. Estimate the Vmax and Km for this patient from the Bayesian nomogram. 2. Estimate the daily dosage of phenytoin required to achieve a target phenytoin serum concentration at steady-state of 60 µmol/l. 3. Estimate the time to 90% of steady-state following initiating the suggested new daily dose. 4. Write a TDM consult note for this patient. 38
39 Exercise #2 Adjustment based on probable values of Vmax and Km and one Css level - Bayesian Nomogram 1. Estimate the Vmax and Km for this patient from the Bayesian nomogram Given: phenytoin sodium dosage = 300 mg/75 kg/day = 4 mg/kg/day observed serum level = 22 µmol/l X 0.25 mg/l = 5.5 mg/l 39
40 Exercise #2 Adjustment based on probable values of Vmax and Km and one Css level - Bayesian Nomogram 1. Estimated Km = 5 mg/l and Estimated Vmax = 7.25 mg/kg/day = 544 mg/day 2. Recommended dose (R) to achieve 15 mg/l (60 µmol/l) R = 5.6 mg/kg/day = 420 mg/day ~ 400 mg/day 3. Time to steady-state on the new daily dose: Time (90%) = Km x Vd (2.3 Vmax 0.9 R), where Vd = 1.0 L/kg (75 L) (Vmax R) 2 Time (90%) = (5 x 75)(2.3 x x 400) = 16.1 days ~ 16 days ( ) 2 40
41 Exercise #2 Adjustment based on probable values of Vmax and Km and one Css level - Bayesian Nomogram 4. THERAPEUTIC DRUG MONITORING (PHENYTOIN) CONSULT This 23 year old man (75 kg) presented to the ER on 0600h with severe head trauma following a MVA. The patient has no significant past medical history, serum creatinine 85 µmol/l, albumin 35 g/l, normal LFTs. An oral maintenance dose of 300 mg phenytoin sodium was started 11 weeks ago and a steady-state serum phenytoin trough level (@ 0800h on ) was 22 µmol/l (therapeutic range µmol/l). Based on the above serum level and Bayesian estimates, this patient has phenytoin pharmacokinetics characterized by a Vmax and Km of 544 mg/day and 4.5 mg/l, respectively. These calculated estimates are similar to those expected for young adults. Based on these pharmacokinetic parameters, we suggest an oral phenytoin sodium capsule dosage of 400 mg/day to achieve anticipated steady-state phenytoin trough serum levels of ~ 60 µmol/l. Repeat steady-state levels could be obtained after 16 days on the recommended dosage just prior to the morning dose. We will continue to follow this patient with you. Thank you for this consult. Jane Smith, BScPhm Pharmacy Ext
42 Exercise #3 Adjustment of phenytoin based on two Css levels at different daily doses (equations) A 65 year old woman (52 kg) with a 25 year history of epilepsy is presently on the following anticonvulsants: phenytoin acid 500 mg daily and carbamazepine 400 mg bid. At an outpatient visit on , a routine serum phenytoin trough level of 18 µmol/l was measured. At that time the patient was receiving phenytoin 300 mg daily and reaffirmed that she was being compliant. The daily dosage was increased on to 500 mg. A repeat steady-state serum phenytoin level of 86 µmol/l was measured on when the patient complained of dizziness. 1. Estimate this patients Vmax and Km values using the 2 sets of levels. 2. Calculate the daily dosage of phenytoin to achieve a level of 60 µmol/l. 3. Estimate the time to 90% of steady-state on the recommended dosage. 4. Write a TDM consult for this patient. 42
43 Exercise #3 Adjustment of phenytoin based on two Css levels at different daily doses (equations) Given: R (mg/day) Css (µmol/l) Css (mg/l) R/Css (L) R = Vmax Km (R/Css) 1. Estimate this patients Km and Vmax values using the 2 sets of levels Km = -slope = - Y2 Y1 = - ( ) = 4.61 mg/l X2 X1 ( ) Vmax = R + (Km x (R /Css)) = (4.61 x 66.67) = 607 mg/day 43
44 Exercise #3 Adjustment of phenytoin based on two Css levels at different daily doses (equations) 2. Calculate the daily dosage of phenytoin to achieve a level of 60 µmol/l. For a desired Css = 15 mg/l R = Vmax x Css = (607)(15) Km + Css ( ) = 464 mg ~ 460 mg R = Sodium phenytoin capsules (4 x 100 mg + 2 x 30 mg) 44
45 Exercise #3 Adjustment of phenytoin based on two Css levels at different daily doses (equations) 3. Estimate the time to 90% of steady-state on the recommended dosage. Time to 90% steady-state: T 90% = Km x Vd (2.3 Vmax 0.9 R) (Vmax R) 2 Where Vd = volume of distribution = 1.0 L/kg = 52 kg R = 460 mg/day T 90% = (4.61)(52)(2.3 x x 460) = 10.9 days (~11 days) ( ) 2 45
46 Exercise #3 Adjustment of phenytoin based on two Css levels at different daily doses (equations) 4. THERAPEUTIC DRUG MONITORING (PHENYTOIN) CONSULT This 65 year old woman (52 kg) with a 25 year history of epilepsy is presently on the following anticonvulsants: phenytoin acid 500 mg daily and carbamazepine 400 mg bid. At an outpatient visit on , a routine serum phenytoin trough level of 18 µmol/l was measured. At that time the patient was receiving phenytoin 300 mg daily and reaffirmed that she was being compliant. The daily dosage was increased on to 500 mg. A repeat steady-state serum phenytoin level of 86 µmol/l was measured on when the patient complained of dizziness. Based on the two sets of levels, this patient has calculated phenytoin disposition constants Km and Vmax of 4.6 mg/l and 607 mg/day, respectively. We recommend a daily phenytoin sodium dosage of 460 mg (4 x 100 mg + 2 x 30 mg) to achieve steady-state phenytoin levels of 60 µmol/l (therapeutic range µmol/l). A repeat serum phenytoin trough level should be obtained after 11 days when the new steadystate is achieved. Thank you for this consult. Jane Smith, BScPhm Pharmacy Ext
CLINICAL PHARMACOKINETICS INDEPENDENT LEARNING MODULE
CLINICAL PHARMACOKINETICS INDEPENDENT LEARNING MODULE Joseph K. Ritter, Ph.D. Assoc. Professor, Pharmacology and Toxicology MSB 536, 828-1022, jritter@vcu.edu This self study module will reinforce the
More informationName: UFID: PHA Exam 2. Spring 2013
PHA 5128 Exam 2 Spring 2013 1 Carbamazepine (5 points) 2 Theophylline (10 points) 3 Gentamicin (10 points) 4 Drug-drug interaction (5 points) 5 Lidocaine (5 points) 6 Cyclosporine (5 points) 7 Phenobarbital
More informationBasic Concepts of TDM
TDM Lecture 1 5 th stage What is TDM? Basic Concepts of TDM Therapeutic drug monitoring (TDM) is a branch of clinical pharmacology that specializes in the measurement of medication concentrations in blood.
More informationPHENYTOIN DOSING INFORMATION. Adult Dosage
PHENYTOIN DRUGDEX Evaluations DOSING INFORMATION Adult Dosage Normal Dosage Important Note ) Due to the risk of severe hypotension and cardiac arrhythmias, the rate of IV phenytoin administration should
More informationClinical Pharmacokinetics. Therapeutic Drug Monitoring of Phenytoin
Clinical Pharmacokinetics Therapeutic Drug Monitoring of Phenytoin Dr. Maysa Suyagh School of Pharmacy University of Jordan Phenytoin primarily used as an anticonvulsant and has been used in the treatment
More informationLD = (Vd x Cp)/F (Vd x Cp)/F MD = (Css x CL x T)/F DR = (Css x (Vm-DR))/Km Css = (F x D)/(CL x T) (Km x DR)/(Vm DR)
PHARMKIN WORKSHOP A PHARMACOKINETICS TEACHING SIMULATION Joseph K. Ritter, Ph.D. Associate Professor, Pharmacology and Toxicology MSB 536, 828-1022, jritter@mail2.vcu.edu Tompkins-McCaw Libray Room 2-006
More informationPHA 5128 Final Exam Spring 2004 Version A. On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5128 Final Exam Spring 2004 Version A On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name There are 18 questions. Total /120 pts Final 2004 1 1. T.P., a 66-year-old,
More informationBasic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy
Basic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy I. General principles Applied pharmacokinetics - the process of using drug concentrations, pharmaco-kinetic
More informationPHA Case Studies V (Answers)
PHA 5128 Case Studies V (Answers) 1. A 100 kg patient is to be treated p.o. with sodium phenytoin capsules. Assuming a phenytoin volume of distribution of 0.7 L/kg, Km of 4 mg/l and Vmax of 7 mg/kg/day,
More informationMyrna Y. Munar, Pharm.D., BCPS
Phenytoin PK Myrna Y. Munar, Pharm.D., BCPS Associate Professor Clickers Turn clicker on by pressing down menu button Enter you OSU student ID number The up/down diagonal arrows button on the left is the
More informationTDM. Generally, hepatic clearance is determined by three main factors: These three factors can be employed in the following equation:
Lecture 9: Very important supplements TDM Effect of hepatic disease on drugs monitoring: Generally, hepatic clearance is determined by three main factors: - Liver blood flow (LBF). - Intrinsic capacity
More information4WS Neurology. Table of Contents
4WS Neurology Table of Contents 1. Phenytoin Preparations... Page 2 Monitoring... Page 2 Therapeutic Range... Page 2 Loading Doses... Page 2 Maintenance Doses... Page 3 Sampling Times... Page 3 Dose Adjustment...
More informationCarbamazepine has a clearance of L/h/kg for monotherapy. For immediate release carbamazepine, the oral bioavailbility is 0.8
PHA 5128 Dose Optimization II, Spring 2013, Case Study IV Solution If you have any questions regarding this case study, do not hesitate to contact Benjamin Weber (benjaminweber@ufl.edu). Please remember
More information. Although there is a little
PHA 58 Spring 007 Case study 4. Baby girl A, 3kg, 5 days, is receiving phenobarbital because of neonatal seizures. An IV loading dose of phenobarbital sodium of 0mg/kg was given followed by maintenance
More informationPHA 5128 Spring 2009 First Exam (Version B)
Name: UFID: PHA 5128 Spring 2009 First Exam (Version B) On my honor, I have neither given nor received unauthorized aid in doing this assignment. Print: Sign: Version B Q1: Phenytoin (10) Q2: procainamide
More informationPHA 5128 Spring 2000 Final Exam
PHA 128 Spring 2000 Final Exam On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name TYPED KEY Questions Points 1. /1 2. /1 3. /1 4. /1. /10 6. /10. /10 8. /10
More informationWhen choosing an antiepileptic ... PRESENTATION... Pharmacokinetics of the New Antiepileptic Drugs. Based on a presentation by Barry E.
... PRESENTATION... Pharmacokinetics of the New Antiepileptic Drugs Based on a presentation by Barry E. Gidal, PharmD Presentation Summary A physician s choice of an antiepileptic drug (AED) usually depends
More informationTDM. Measurement techniques used to determine cyclosporine level include:
TDM Lecture 15: Cyclosporine. Cyclosporine is a cyclic polypeptide medication with immunosuppressant effect. It has the ability to block the production of interleukin-2 and other cytokines by T-lymphocytes.
More informationNonlinear Pharmacokinetics
Nonlinear Pharmacokinetics Non linear pharmacokinetics: In some cases, the kinetics of a pharmacokinetic process change from predominantly first order to predominantly zero order with increasing dose or
More informationValproate Case 3: Formulations Jose de Leon, MD
Valproate Case 3: Formulations 2-12-16 Jose de Leon, MD 3.Valproate Case 3 Described in J Clin Psychiatry 2004;65:724-5 http://www.ncbi.nlm.nih.gov/pubmed/15163266 Pharmacological explanation provided
More informationTDM of Digoxin. Use of Digoxin Serum Concentrations to Alter Dosages
TDM Lecture 8 5 th Stage TDM of Digoxin Use of Digoxin Serum Concentrations to Alter Dosages Linear Pharmacokinetics Method This method is used in steady-state condition. We compute the new dose of digoxin
More informationPHA 5128 Case Study 4 (Answers) Total Cp = Unbound Cp/fu.
PHA 58 ase Study 4 (Answers) Spring 4. PT is a patient stabilized on chronic phenytoin therapy. She has just been diagnosed with rheumatoid arthritis and her physician would like to start her on high dose
More informationTDM Lecture 7 5 th Stage. TDM of Digoxin. Uses: Digoxin is usually used in heart failure associated and atrial fibrillation.
TDM Lecture 7 5 th Stage TDM of Digoxin Digoxin uses and elimination Uses: Digoxin is usually used in heart failure associated and atrial fibrillation. Elimination: About 75% of digoxin clearance occurred
More informationDoses Target Concentration Intervention
1 Doses Target Concentration Intervention 2 Problem 1 Questions 1-2 Susan is a 28 year old woman who has had epilepsy since she was 5 years old. She has been on, and off, anticonvulsant medication since
More informationADME Review. Dr. Joe Ritter Associate Professor of Pharmacology
ADME Review Dr. Joe Ritter Associate Professor of Pharmacology 828-1022 jkritter@vcu.edu What percent of a weak base (pka = 7.5) and weak acid (pka = 3.5) will be respectively ionized in urine of ph 5.5?
More informationTDM of Aminoglycoside Antibiotics
TDM Lecture 3 5 th Stage TDM of Aminoglycoside Antibiotics The aminoglycoside antibiotics are widely used for the treatment of gram-negative infections, often in combination with a β-lactam antibiotic
More informationNew drugs necessity for therapeutic drug monitoring
New drugs necessity for therapeutic drug monitoring Stephan Krähenbühl Clinical Pharmacology & Toxicology University Hospital Basel kraehenbuehl@uhbs.ch Drugs suitable for TDM Narrow therapeutic range
More informationValproate Case 1: Pharmacokinetics Jose de Leon, MD
Valproate Case 1: Pharmacokinetics 2-12-16 Jose de Leon, MD 1. Valproate Case 1 J Clin Psychopharmacology 2009;29:509-11 http://www.ncbi.nlm.nih.gov/pubmed/19745660 Educational Objectives At the conclusion
More informationPHARMACOKINETICS SMALL GROUP II:
PHARMACOKINETICS SMALL GROUP II: Question 1 Why are some drug therapies initiated with a loading dose? Emphasize that LD establishes initial therapeutic level quickly. The time to reach the steady-state
More informationPHARMACOKINETICS SMALL GROUP I:
PHARMACOKINETICS SMALL GROUP I: Question 1 Absorption of the anti-fungal agent, itraconazole, is dependent on a low gastric ph. Calculate the relative concentrations of a weak acid (with a pka of 5.4)
More informationPHA5128 Dose Optimization II Case Study I Spring 2013
Silsamicin is an investigational compound being evaluated for its antimicrobial effect. The route of administration for this drug is via intravenous bolus. Approximately 99.9% of this drug is eliminated
More informationI. Introduction Epilepsy is the tendency to have recurrent seizures unprovoked by systemic or acute neurologic insults. Antiepileptic drugs (AEDs)
1 2 I. Introduction Epilepsy is the tendency to have recurrent seizures unprovoked by systemic or acute neurologic insults. Antiepileptic drugs (AEDs) are those which decrease the frequency and/or severity
More informationGeneral Principles of Pharmacology and Toxicology
General Principles of Pharmacology and Toxicology Parisa Gazerani, Pharm D, PhD Assistant Professor Center for Sensory-Motor Interaction (SMI) Department of Health Science and Technology Aalborg University
More informationDisclosures. AED Options. Epilepsy Pharmacotherapy: Treatment Considerations with Older AEDs
Epilepsy Pharmacotherapy: Treatment Considerations with Older AEDs BARRY E. GIDAL, PHARMD PROFESSOR SCHOOL OF PHARMACY & DEPT. OF NEUROLOGY Disclosures Speaking honoraria: UCB, Eisai, Sunovion Consultant:
More informationPharmacokinetic parameters: Halflife
Pharmacokinetic parameters: Halflife (t 1/2 ) 1. By definition t 1/2 is the time required for the concentration to fall by one half. For drugs with first order kinetics this is a constant. 2. Half-life
More informationBasic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics
Basic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics Learning Outcomes Define biopharmaceutics Describe 4 processes of pharmacokinetics Describe factors that affect medication absorption Describe
More informationBIOPHARMACEUTICS and CLINICAL PHARMACY
11 years papers covered BIOPHARMACEUTICS and CLINICAL PHARMACY IV B.Pharm II Semester, Andhra University Topics: Absorption Distribution Protein binding Metabolism Excretion Bioavailability Drug Interactions
More informationUSES OF PHARMACOKINETICS
CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program Office of Clinical Research Training and Medical Education National Institutes of Health Clinical Center
More informationSection 5.2: Pharmacokinetic properties
Section 5.2: Pharmacokinetic properties SmPC training presentation Note: for full information refer to the European Commission s Guideline on summary of product characteristics (SmPC) SmPC Advisory Group
More informationPHA Spring First Exam. 8 Aminoglycosides (5 points)
PHA 5128 Spring 2012 First Exam 1 Aminoglycosides (5 points) 2 Aminoglycosides (10 points) 3 Basic Principles (5 points) 4 Basic Principles (5 points) 5 Bioavailability (5 points) 6 Vancomycin (5 points)
More informationimproving the patient s quality of life.
Epilepsy is the tendency to have recurrent seizures unprovoked by systemic or acute neurologic insults. Antiepileptic drugs (AEDs) are those which decrease the frequency and/or severity of seizures in
More informationIntroduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
Introduction to 1 Pharmacokinetics University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 2 Learning objectives Understand compartment models and how they effects
More informationBASIC PHARMACOKINETICS
BASIC PHARMACOKINETICS MOHSEN A. HEDAYA CRC Press Taylor & Francis Croup Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business Table of Contents Chapter
More informationChapter-V Drug use in renal and hepatic disorders. BY Prof. C.Ramasamy, Head, Dept of Pharmacy Practice SRM College of Pharmacy, SRM University
Chapter-V Drug use in renal and hepatic disorders. BY Prof. C.Ramasamy, Head, Dept of Pharmacy Practice SRM College of Pharmacy, SRM University Estimating renal function An accurate estimation of renal
More informationDrug Dosing in Renal Insufficiency. Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila
Drug Dosing in Renal Insufficiency Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila Declaration of Conflict of Interest For today s lecture on Drug Dosing in Renal
More informationEPILEPSY: SPECTRUM OF CHANGE WITH AGE. Gail D. Anderson, Ph.D.
EPILEPSY: SPECTRUM OF CHANGE WITH AGE Gail D. Anderson, Ph.D. Incidence: 0.5% - 1.0% of U.S. population Peak incidence of onset: first 2 years of life, ages 5-7 years, early puberty and elderly. 125,000
More informationPharmacokinetics Overview
Pharmacokinetics Overview Disclaimer: This handout and the associated lectures are intended as a very superficial overview of pharmacokinetics. Summary of Important Terms and Concepts - Absorption, peak
More informationLippincott Questions Pharmacology
Lippincott Questions Pharmacology Edition Two: Chapter One: 1.Which one of the following statements is CORRECT? A. Weak bases are absorbed efficiently across the epithelial cells of the stomach. B. Coadministration
More informationPHA Second Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Second Exam Fall 2013 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question/Points Set I 20 pts Set II 20 pts Set III 20 pts Set IV 20 pts Set
More informationIt the process by which a drug reversibly leaves blood and enter interstitium (extracellular fluid) and/ or cells of tissues.
It the process by which a drug reversibly leaves blood and enter interstitium (extracellular fluid) and/ or cells of tissues. Primarily depends on: 1.Regional blood flow. 2.Capillary permeability. 3.Protein
More informationThus, we can group the entire loading dose together as though it was given as a single dose, all administered when the first dose was given.
PHA 5128 Dose Optimization II, Spring 2012, Case Study V Solution If you have any questions regarding this case study, do not hesitate to contact Benjamin Weber (benjaminweber@ufl.edu). Please remember
More information1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?
Page 1 PHAR 750: Biopharmaceutics/Pharmacokinetics October 23, 2009 - Form 1 Name: Total 100 points Please choose the BEST answer of those provided. For numerical answers, choose none of the above if your
More informationPHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Second Exam Fall 2011 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Put all answers on the bubble sheet TOTAL /200 pts 1 Question Set I (True or
More informationPHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Final Exam Fall 2012 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Please transfer the answers onto the bubble sheet. The question number refers
More informationPHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Final Exam Fall 2010 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Please transfer the answers onto the bubble sheet. The question number refers
More informationNontraditional PharmD Program PRDO 7700 Pharmacokinetics Review Self-Assessment
Nontraditional PharmD Program PRDO 7700 Pharmacokinetics Review Self-Assessment Please consider the following questions. If you do not feel confident about the material being covered, then it is recommended
More informationpharmacy, we need to see how clinical pharmacokinetics fits into the pharmaceutical care process.
Therapeutic drug monitoring (TDM) Is a tool that can guide the clinician to provide effective and safe drug therapy in the individual patient. Monitoring can be used to confirm a plasma drug concentration
More informationNONLINEAR PHARMACOKINETICS: INTRODUCTION
Print Close Window Note: Large images and tables on this page may necessitate printing in landscape mode. Applied Biopharmaceutics & Pharmacokinetics > Chapter 9. Nonlinear Pharmacokinetics > NONLINEAR
More informationMultiple IV Bolus Dose Administration
PHARMACOKINETICS Multiple IV Bolus Dose Administration ١ Multiple IV Bolus Dose Administration Objectives: 1) To understand drug accumulation after repeated dose administration 2) To recognize and use
More informationPHA 5127 FINAL EXAM FALL On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 FINAL EXAM FALL 1997 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question Points 1. /14 pts 2. /10 pts 3. /8 pts 4 /8 pts 5. /12 pts 6. /8 pts
More informationM O N T H E R A P E D R O R I N G. Dr Tom Hartley UTAS HLS 2014
T H E R A P E U T I C D R U G M O N I T O R I N G Dr Tom Hartley UTAS HLS 2014 TOPICS 1) Why we do TDM 2) What drugs do we monitor 3) How our data assists Clinical Pharmacists & Doctors 4) Bioavailability
More informationPHA5128 Dose Optimization II Case Study 3 Spring 2013
Use the vancomycin dosing nomogram table below: A female patient, 57 years of age, 5 6 in height and 100 in weight had an infection requiring vancomycin treatment. Her serum creatinine was 0.8 mg/d. What
More informationSEIZURES PHARMACOLOGY. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
SEIZURES PHARMACOLOGY University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 Understand the pharmacodynamics involved in the medications used to treat seizures
More informationBiopharmaceutics. Tips Worth Tweeting. Contributor: Sandra Earle
Biopharmaceutics C H A P T E R 2 Contributor: Sandra Earle The physiochemical properties of drugs determine how they will move and interact with the body. By understanding a few principles, predictions
More informationPrinciples of Medication Use in Older Adults ANNE L. HUME, PHARMD PROFESSOR OF PHARMACY UNIVERSITY OF RHODE ISLAND
Principles of Medication Use in Older Adults ANNE L. HUME, PHARMD PROFESSOR OF PHARMACY UNIVERSITY OF RHODE ISLAND Financial Disclosure None of the planners, speakers, and/or members of the CME committee
More informationTEACHERS TOPICS Role of Protein Binding in Pharmacokinetics
TEACHERS TOPICS Role of Protein Binding in Pharmacokinetics Reza Mehvar, PhD School of Pharmacy, Texas Tech University Health Sciences Center Submitted January 3, 2005; accepted February 13, 2005; published
More informationEach tablet contains:
Composition: Each tablet contains: Tolvaptan 15/30mg Pharmacokinetic properties: In healthy subjects the pharmacokinetics of tolvaptan after single doses of up to 480 mg and multiple doses up to 300 mg
More informationSelected Clinical Calculations Chapter 10. Heparin-Dosing calculations
Selected Clinical Calculations Chapter 10 Heparin-Dosing calculations Heparin is a heterogeneous group of muco-polysaccharides that have anticoagulant properties (slows clotting time). Heparin salt, as
More information2015 Updates in Therapeutics: The Pharmacotherapy Preparatory Review & Recertification Course Pharmacokinetics: A Refresher Curtis L.
2015 Updates in Therapeutics: The Pharmacotherapy Preparatory Review & Recertification Course Pharmacokinetics: A Refresher Curtis L. Smith, Pharm.D., BCPS Ferris State University Conflict of Interest
More informationPharmacokinetics One- compartment Open Model Lec:2
22 Pharmacokinetics One- compartment Open Model Lec:2 Ali Y Ali BSc Pharmacy MSc Industrial Pharmaceutical Sciences Dept. of Pharmaceutics School of Pharmacy University of Sulaimani 1 Outline Introduction
More informationDEPARTMENT OF PHARMACOLOGY AND THERAPEUTIC UNIVERSITAS SUMATERA UTARA
METABOLISME dr. Yunita Sari Pane DEPARTMENT OF PHARMACOLOGY AND THERAPEUTIC UNIVERSITAS SUMATERA UTARA Pharmacokinetic absorption distribution BIOTRANSFORMATION elimination Intravenous Administration Oral
More informationICU Volume 11 - Issue 3 - Autumn Series
ICU Volume 11 - Issue 3 - Autumn 2011 - Series Impact of Pharmacokinetics of Antibiotics in ICU Clinical Practice Introduction The efficacy of a drug is mainly dependent on its ability to achieve an effective
More informationAminoglycosides. Uses: Treatment of serious gram-negative systemic infections and some grampositive
Aminoglycosides Uses: Treatment of serious gram-negative systemic infections and some grampositive infections such as infective endocarditis. Disadvantage: aminoglycosides are their association with nephrotoxicity
More informationDrug dosing in Extremes of Weight
Drug dosing in Extremes of Weight The Plump & Heavy versus The Skinny & Light Maria Minerva P. Calimag, MD, MSc, PhD, DPBA, FPSECP PROFESSOR Departments of Pharmacology, Anesthesiology and Clinical Epidemiology
More informationPolicy: Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing
ProMedica Health System Clinical Interdepartmental Policy and Procedure: Section: Policy: Date: Subject: Pharmacy Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing
More informationComparing Methods for Once Daily Tobramycin Exposure Predictions in Children with Cystic Fibrosis
Comparing Methods for Once Daily Tobramycin Exposure Predictions in Children with Cystic Fibrosis Stefanie HENNIG, Franziska STILLER, Beverly TEO, Christine STAATZ, Brisbane Cystic fibrosis (CF) & Once
More informationEffects of Liver Disease on Pharmacokinetics
Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program October 31, 2013 National Institutes of Health Clinical Center 1 GOALS of Effects of Liver
More information(Max 2 g) = to nearest 250 mg
Appendix 1 (part 1 of 8): Rubric for competency assessment of pharmacists prescribing and managing vancomycin Empiric Dosing Phase Pts Yes No Data Error OP Did the pharmacist document the indication 2
More informationSHC Vancomycin Dosing Guide
SHC Vancomycin Dosing Guide A: Initial dosing considerations B. Pharmacodynamic Targets: goal AUC and troughs C. Loading dose D: Initial Vancomycin Maintenance Dosing and Serum Concentration Monitoring
More informationOne-Compartment Open Model: Intravenous Bolus Administration:
One-Compartment Open Model: Intravenous Bolus Administration: Introduction The most common and most desirable route of drug administration is orally by mouth using tablets, capsules, or oral solutions.
More informationEdoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor
This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review
More information2016 Treatment Algorithm for Generalized Convulsive Status Epilepticus (SE) in adults and children > 40 kg
Yale New Haven Health Department of Pharmacy, Department of Neurology 2016 Treatment Algorithm for Generalized Convulsive Status Epilepticus (SE) in adults and children > 40 kg Guideline, YNHHS Original
More informationBasic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations
Basic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations Rosenbaum, Sara E. ISBN-13: 9780470569061 Table of Contents 1 Introduction to Pharmacokinetics and Pharmacodynamics.
More informationReview of Anticonvulsant Medications: Traditional and Alternative Uses. Andrea Michel, PharmD, CACP
Review of Anticonvulsant Medications: Traditional and Alternative Uses Andrea Michel, PharmD, CACP Objectives Review epidemiology of epilepsy Classify types of seizures Discuss non-pharmacologic and pharmacologic
More informationChallenges in Therapeutic Drug Monitoring:
Challenges in Therapeutic Drug Monitoring: Focus on Vancomycin Pharmacodynamics and Pharmacokinetics Katherine Gallaga, PharmD PGY1 Pharmacy Practice Resident CHRISTUS Spohn Health System 1 Pharmacist
More informationPediatric Pharmacotherapy
Pediatric Pharmacotherapy A Monthly Review for Health Care Professionals of the Children's Medical Center Volume 1, Number 7, July 1995 Therapeutic Drug Monitoring in Pediatric Patients Therapeutic Drug
More informationSedative-Hypnotics. Sedative Agents (General Considerations)
Sedative Agents (General Considerations) No best sedative agent Any agent given in sufficient dosage can produce any level of sedation Intravenous dosing is more predictable then intramuscular or oral
More informationAMINOGLYCOSIDES TDM D O N E B Y
AMINOGLYCOSIDES TDM DONE BY: SARA ALARFAJ 2014 OUTLINE Introduction about Aminoglycosides. Spectrum/uses. TDM Aminoglycosides TDM Pharmacodynamics Pharmacokinetics. Dosing in AG. Sampeling time and Monitoring.
More informationLearning Outcomes. Overall Picture. Part 1 Overview of Key Concepts of Clinical Pharmacokine2cs 4/23/14. A- Awaisu- A- Nader- CPPD
Learning Outcomes CPPD #7 Clinical Pharmacokine2cs: Concepts and Prac2ce Applica2ons Ahmed Nader, Ph.D, BCPS Ahmed Awaisu, Ph.D, B.Pharm Upon comple;on of this session, audience are expected to be able
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationDrug Disposition in Obesity & Protein-Calorie Malnutrition
Drug Disposition in Obesity & Protein-Calorie Malnutrition JBoullata, PharmD, RPh, BCNSP Associate Professor of Pharmacology & Therapeutics -and- Pharmacy Specialist in Nutrition Support University of
More informationIntroduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
Introduction to 1 Pharmacokinetics University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 2 Learning objectives Understand compartment models and how they effects
More informationDEPAKOTE ER DIVALPROEX SODIUM EXTENDED-RELEASE TABLETS R x Only
Page 1 (No. 3826 and, 7126) 03-5235-R4-Rev. December, 2002 NEW DEPAKOTE ER DIVALPROEX SODIUM EXTENDED-RELEASE TABLETS R x Only BOX WARNING: HEPATOTOXICITY: HEPATIC FAILURE RESULTING IN FATALITIES HAS OCCURRED
More informationPHA Final Exam Fall 2006
PHA 5127 Final Exam Fall 2006 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Please transfer the answers onto the bubble sheet. The question number refers
More informationPharmacokinetics of Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Pharmacokinetics of Drugs Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Absorption Is the transfer of a drug from its site of administration to the bloodstream.
More informationPHA First Exam Fall 2003
PHA 5127 First Exam Fall 2003 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question/Points 1. /14 pts 2. /6 pts 3. /15 pts 4. /12 pts 5. /20 pts 6. /10pts
More informationInvestigational Pharmacy Cannabidiol treatment in Epilepsy
Jon Beck BS Pharm D Coordinator Investigational Pharmacy Disclosure I have no relevant financial relationships with a Commercial Provider Nebraska Medicine Omaha, NE Investigational Pharmacy Cannabidiol
More informationPEDIATRIC PHARMACOTHERAPY
PEDIATRIC PHARMACOTHERAPY A Monthly Newsletter for Health Care Professionals from the Children s Medical Center at the University of Virginia Volume 7 Number 11 November 2001 A Oxcarbazepine Use in Children
More informationTherapeutic drug monitoring. Department of Clinical Pharmacology, Wrocław Medical University
Therapeutic drug monitoring Department of Clinical Pharmacology, Wrocław Medical University Therapeutic index concentration range characterized by a high efficacy of action and low risk of upper toxic
More information